Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/Safety of MSB11022 vs Humira in Healthy Subjects
NCT03014947Phase 1Completed
- Sponsor
- Fresenius Kabi
- Start
- May 2014
- Primary completion
- Dec 2014
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, randomised, double-blind trial of adalimumab in rheumatoid arthritis (RA), plaque psoriasis, Crohn's disease and 4 more (3 arms), sponsored by Fresenius Kabi. Primary endpoints: Area Under the Concentration-Time Curve From time Zero Extrapolated to Infinity at 1680 hours, Maximum Observed Serum Concentration at 1680 hours and 1 more. Started May 2014; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)plaque psoriasisCrohn's diseaseulcerative colitis (UC)ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT03014947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03014947.